Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

Executive Summary

• Red Light Holland Corp. has engaged Kala Bio, Inc. to license its Researgency.ai agentic AI platform to support the clinical development strategy for PEX010, a patented botanical psilocybin drug candidate.
• This engagement coincides with Red Light’s definitive arrangement agreement to acquire Filament Health Corp., which owns PEX010 and a portfolio of 76 issued patents.
• The AI platform will be used to accelerate clinical planning, protocol optimization, and scenario modeling for PEX010, which is currently in clinical trials for multiple indications including alcohol use disorder and treatment-resistant depression.

Key Details

• Partnership Structure: Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) entered into a worldwide license agreement with Kala Bio, Inc. (NASDAQ: KALA) for the Researgency.ai platform.
• Technology Details: Researgency.ai is an agentic AI platform developed by Younet.ai, with exclusive worldwide distribution/development rights owned by Kala Bio. It deploys secure, on-premises AI agents trained by Younet engineers under private cloud LLM infrastructure to simulate scenarios, optimize protocols, and support evidence-driven decisions in pharmaceutical R&D.
• M&A Context: The AI engagement supports Red Light’s acquisition of Filament Health Corp. The acquisition includes Filament’s lead drug candidate, PEX010, and a portfolio of 76 issued patents across 15 patent families, described as one of the largest intellectual property portfolios in botanical psilocybin drug development.
• Drug Candidate (PEX010):
  • Origin: Patented botanical psilocybin drug candidate originated by Filament Health Corp.
  • Status: Currently supplied to more than 70 clinical research sites worldwide; authorized for clinical trials by both Health Canada and the U.S. FDA.
  • Clinical Data: Has demonstrated positive Phase 2 clinical data in alcohol use disorder.
  • Indications: Being studied for alcohol use disorder, methamphetamine use disorder, treatment-resistant depression, cancer-related anxiety and depression, and cannabis use disorder.
  • Key Institutions: Trials are underway at leading research institutions including Johns Hopkins University and Dana-Farber Cancer Institute.
• Strategic Rationale: Red Light intends to use the AI agents to accelerate research planning, scenario simulation, and protocol optimization to advance PEX010 through its regulated drug development program.

Notable Quotes

• Todd Shapiro, CEO of Red Light Holland: “As we move to integrate Filament’s exceptional clinical assets and intellectual property, engaging Kala Bio’s Researgency.ai platform is a natural next step in building a best-in-class psychedelic drug development operation... By applying autonomous AI-driven research capabilities to our clinical development planning, we believe we can accelerate timelines, strengthen study designs, and make smarter, faster decisions across PEX010’s extensive clinical program.”
• Ben Lightburn, CEO of Filament Health: “With PEX010 already supporting a growing body of global clinical research, the application of advanced analytical tools such as Kala Bio’s Researgency.ai platform has the potential to further strengthen how clinical development strategies are evaluated as the program continues to evolve.”
• Avi Minkowitz, CEO of Kala Bio: “Red Light’s decision to deploy Researgency.ai in support of PEX010 underscores exactly the kind of high-value, data-intensive challenge our platform was built to address... We are excited to work with the Red Light team as they advance one of the leading botanical psilocybin programs in the world.”